Because sarcopenia worsens prognosis in cirrhosis, the pattern seen with SGLT2 inhibition, preferential fat-mass loss accompanied by small but measurable lean-mass reductions, argues for nutrition-aware initiation with longitudinal tracking of weight, strength, and electrolytes in this population [183,184]. This evidence concerns the gene SLC5A2 and Cirrhosis.